Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies (AIA) is a rare, acquired immunodeficiency disorder characterized by the presence of autoantibodies directed against interferon-gamma (IFN-γ). These autoantibodies interfere with the normal function of IFN-γ, which is an important cytokine involved in the regulation of the immune system. Patients with AIA typically present with recurrent infections, including bacterial, fungal, and viral infections, as well as autoimmune disorders. Treatment of AIA is typically focused on controlling the underlying autoimmune disorder and preventing recurrent infections.

The symptoms of Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies can vary from person to person, but may include:

-Recurrent infections, such as sinusitis, bronchitis, pneumonia, and urinary tract infections
-Frequent and severe viral infections, such as herpes simplex virus, cytomegalovirus, and Epstein-Barr virus
-Fungal infections, such as candidiasis
-Bacterial infections, such as tuberculosis
-Autoimmune diseases, such as lupus and rheumatoid arthritis
-Inflammatory bowel disease
-Skin rashes
-Fatigue
-Fever
-Weight loss
-Night sweats
-Enlarged lymph nodes

The exact cause of adult-onset immunodeficiency with anti-interferon-gamma autoantibodies is unknown. However, it is believed to be an autoimmune disorder, meaning that the body’s immune system mistakenly attacks its own healthy cells and tissues. Possible triggers for this disorder include infections, certain medications, and environmental factors.

1. Immunosuppressive therapy: This involves the use of medications such as corticosteroids, cyclophosphamide, and azathioprine to suppress the immune system and reduce the production of autoantibodies.

2. Intravenous immunoglobulin (IVIG): This involves the administration of high doses of immunoglobulins, which are proteins that help the body fight infection.

3. Plasmapheresis: This is a procedure in which the patient’s blood is removed and filtered to remove the autoantibodies.

4. Rituximab: This is a monoclonal antibody that targets and destroys B cells, which are responsible for producing autoantibodies.

5. Immunomodulatory therapy: This involves the use of medications such as inter

1. Age: Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies is more common in adults over the age of 40.

2. Gender: Women are more likely to develop this condition than men.

3. Genetics: Certain genetic mutations may increase the risk of developing this condition.

4. Autoimmune diseases: People with other autoimmune diseases, such as lupus or rheumatoid arthritis, may be at an increased risk of developing this condition.

5. Exposure to certain medications: Certain medications, such as interferon-gamma, may increase the risk of developing this condition.

At this time, there is no known cure for Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies. Treatment focuses on managing symptoms and preventing infections. Medications such as immunoglobulin replacement therapy, corticosteroids, and other immunosuppressants may be used to help reduce inflammation and improve immune system function. Additionally, lifestyle modifications such as avoiding contact with people who are ill, getting adequate rest, and eating a healthy diet may help to reduce the risk of infection.